Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Acute 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1Leukemia, Basophilic, Acute 1GATA2 Deficiency 1

Interventions

Cytarabine 11tipifarnib 4Sorafenib 3Idarubicin 3Etoposide 3Daunorubicin 3tanespimycin 2laromustine 2alvocidib 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Gene Expression Profiling 2Decitabine 2DNA Methylation 2Busulfan 2Bortezomib 2Azacitidine 2valspodar 1romidepsin 1fludarabine phosphate 1entinostat 1aldesleukin 1XK 469 1Watchful Waiting 1Vorinostat 1Observation 1Microarray Analysis 1Melphalan 1Lenalidomide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Basophilic, Acute × Injections × Clear all
NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
178 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡